Free guide · A printable companion

A Woman's Guide to Peptide Therapy.

A printable companion to Anthivera — the questions to bring to your first consult, a one-page peptide chart, and the 2026 regulatory timeline at a glance. 8 pages, designed to print and write on.

May 2026 edition · 8 pages

We'll send the PDF and add you to Anthivera Insider (one careful email a week). Unsubscribe anytime.

The PDF is the companion, not the archive

The website is the deep, current source — long-form articles, the live provider comparison, and a weekly dispatch as the landscape evolves. The PDF is what you print, write on, and hand to a clinician. Tactile tools, not duplicated content.

What's inside

  • 01

    A printable first-consult checklist

    Twelve questions worth asking before you start. Designed to print, with space for the provider's answers — bring it to your appointment.

  • 02

    A one-page peptide-comparison chart

    Every peptide we cover side by side — category, FDA status, women's relevance, strength of evidence — on a single sheet you can scan in 60 seconds.

  • 03

    The 2026 regulatory timeline, as a graphic

    Category 2 (2023) → removed for ~12 peptides (April 2026) → PCAC review (July 2026), in one clear graphic. Always verify current status with a provider.

  • 04

    The red-flag spotter

    How to recognize gray-market vendors, unsafe providers, and the marketing tactics worth running from. A short list, written for women, easy to share.

The guide is editorial. It compares and informs — it doesn't recommend treatment for any condition. See our medical disclaimer. Regulatory information is current as of May 2026 and may change; always verify with a licensed clinician.